Differentiating Rheumatoid Arthritis, Psoriatic Arthritis, and Posterior Tibial Tendon Dysfunction

Key Distinguishing Features

The presence of psoriatic plaques or nail psoriasis establishes PsA, while their absence with rheumatoid nodules, extra-articular involvement, or high-titer rheumatoid factor confirms RA, according to the American Academy of Dermatology 1
Skin and nail assessment is crucial, as psoriatic plaques or nail changes strongly favor PsA over RA, with a study suggesting psoriasis typically precedes joint symptoms by an average of 12 years in 84% of PsA patients 2, 1, 3
The joint distribution pattern differs between RA and PsA, with RA characterized by symmetric polyarticular involvement, typically sparing DIP joints, and PsA showing a less symmetric distribution, with joints usually less tender and swollen than RA 4, 2, 1, 5
DIP joint involvement strongly suggests PsA, as this is uncommon in RA 2, 1, 5
Pathognomonic features for PsA include dactylitis and enthesitis, which are uncommon in RA 2, 1, 5, 6

For RA diagnosis, rheumatoid factor and anti-citrullinated protein antibody are used, with high positive results adding points to the ACR/EULAR classification, according to the Mayo Clinic Proceedings 4
For PsA, no specific serologic tests confirm the diagnosis, but rheumatoid factor should be negative, and elevated acute phase reactants support inflammatory arthritis but are nonspecific 1, 7, 2

The diagnostic algorithm involves examining skin and nails first, assessing joint pattern, checking RF and ACPA, looking for RA-specific features, and evaluating for PTTD, with the American Academy of Dermatology recommending a step-by-step approach 1, 2, 4

Early diagnosis is critical, as both RA and PsA can cause progressive joint damage within the first year, leading to severe physical limitations and disability if untreated, according to the American Academy of Dermatology 3, 6
For PsA, treatment depends on disease severity, with mild disease responding to NSAIDs, moderate disease requiring DMARDs or TNF blockers, and severe disease requiring DMARDs plus TNF blockers or other biologics 1
For RA, early DMARD therapy is essential, with methotrexate typically being first-line, according to the Mayo Clinic Proceedings 4